A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
6 Months
20 Years
Both
Burkitt Lymphoma
Trial Information
A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents
with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the
response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3
acute leukemia, diffuse large B-cell lymphoma and non subclassified aggressive B-cell NHL.
The secondary objectives are to assess the toxicity profile of Rituximab in children and
adolescents as single agent, and when followed by chemotherapy, to study pharmacokinetics of
Rituximab in serum and in CSF and to determine the overall duration of response, time to
progression and survival in patients responders to antiCD20 initially alone and followed by
chemotherapy.
Patients will receive Rituximab (Mabthera) at 375 mg/m2, once a week during 4 weeks,
administered in IV infusion starting at 50mg/h and increasing by steps of 50 mg/h every 30mn
until the speed of 400 mg/h. Patients with combined CNS relapse will receive an intrathecal
injection of MTX+HC+Ara-C 48 h after each injection of rituximab First assessment will be
done prior to receiving the 3rd course of rituximab. Responding patients (CR, PR) and
patients with objective effect (OE) will receive the 3rd and 4th injections of rituximab
before starting the salvage chemotherapy (COPADM, CYVE/CC course or ICE, depending on
previous chemotherapy regimen received by the patient, followed by HDCT+ hematopoietic stem
cell rescue). A second evaluation will be done after the 4th course if performed.
Inclusion Criteria:
- Histologically or cytologically proven B-cell malignancies, either Burkitt NHL or L3
ALL or large B-cell lymphoma or aggressive B-cell NHL, with the exception of diffuse
large B-cell lymphoma arising in the mediastinum.
- Immunohistochemistry showing CD20 positivity
- Measurable (at least one bi-dimensionally measurable lesion) or evaluable (bone
marrow, bone involvement) disease in progression since the last evaluation
- First relapsed or refractory disease after LMB or BFM protocol, except the isolated
CNS relapses
- Life expectancy > 4 weeks
- Performance status (Karnofsky) > 30
- Adequate hepatic, renal and cardiac functions
- Wash out of 3 weeks in case of recent chemotherapy
- Complete initial work-up within 8 days prior to treatment
- Able to comply with scheduled follow-up and with management of toxicity
- Written inform consent form from adult patients and from parents and legal guardians
for minor children
Exclusion Criteria:
- Active viral infection, especially chronic hepatitis B
- previous salvage therapy for relapse
- Prior or current history of severe allergy
- Primary large B-cell lymphoma of the mediastinum
- Isolated CNS relapse
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Rate of patients achieving at least objective response after 2 courses of rituximab
Principal Investigator
Catherine Patte, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Gustave Roussy, Cancer Campus, Grand Paris
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
Rituximab childhood
NCT ID:
NCT00180895
Start Date:
June 2004
Completion Date:
Related Keywords:
- Burkitt Lymphoma
- Burkitt lymphoma
- B-cell non Hodgkin lymphoma
- B-cell ALL
- Refractory
- Relapse
- Rituximab
- Children
- Burkitt Lymphoma
- Lymphoma
Name | Location |
|---|
